CClinicalTrials.gg
CompletedNCT04680403Updated Feb 2, 2026

Video Telehealth Exercise Training in Cystic Fibrosis

An interventional study of Exercise in Cystic Fibrosis, sponsored by University of Alabama at Birmingham. Completed at 1 site in United States. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-02-02.

Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
19 Years and older
Sex
All
01

Study summary

The purpose of this research study is to begin an exercise program for patients with a cystic fibrosis (CF) exacerbation.

Read the detailed description

The study will enroll 25 patients with CF during an introduction visit and initiate an ambulatory 1) tailored exercise regimen and 2) behavior change techniques focused on adherence and sustainability of exercise. The intervention will be delivered via a data-enabled smartphone with video capabilities facilitating live and interactive two-way video-conferencing using a HIPAA compliant app. Participants will receive supervised exercise paired with coaching on behavior change techniques over 12 weeks in 3 weekly 1-hour sessions, and will have monthly phone follow-ups and clinic follow-ups at 3 and 6 months.

02

Conditions studied

  • Cystic Fibrosis

Browse trials for

03

In context

Cystic Fibrosis

1,581 studies on the registry are indexed under Cystic Fibrosis; 190 are open to participants now.

This study's enrollment of 9 is below the median of 36 across 1,034 interventional studies indexed under Cystic Fibrosis.

Browse Cystic Fibrosis studies →

Lead sponsor

University of Alabama at Birmingham is the lead sponsor of 1,396 studies on the registry; 284 are open to participants now.

Of its 156 completed or terminated interventional studies of FDA-regulated products, 124 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

Diagnosed with Cystic Fibrosis 18 years old and older clinically stable with no exacerbation within 6 weeks

Exclusion criteria

Exclusion Criteria:

any comorbidity that precludes exercise

-

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    supervised exercise plan

    patients will receive a tailored exercise regimen and behavior change techniques focused on adherence to the exercise program. These will be delivered by using a video platform, much liker telehealth clinic appointments. These telehealth visits will be over a 12-week period, occur 3 times a week, and last for 1 hour each.

    Other: Exercise

Interventions

  • OtherExercise

    supervised exercise paired with coaching on behavior change techniques over 12 weeks (3 weekly sessions) and will have monthly phone follow-ups and clinic follow-ups after 3 and 6 months.

    Also known as: Behavior Change Coaching

06

What researchers measure

Primary outcomes

  1. Feasibility and acceptability

    Feasibility and acceptability will include patients willingness to participate

    Time frame: 6 months

07

Study locations

1 site
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
08

References and documents

Publications

  • Saag J, Bergeron J, Bailey J, Monroe K, Hathorne H, Solomon GM, Lowman JD, Bhatt SP, Garcia B, Krick S. Pilot and Feasibility Study of an Individualized Telehealth Exercise Program for People with Cystic Fibrosis. J Funct Morphol Kinesiol. 2026 Mar 26;11(2):136. doi: 10.3390/jfmk11020136. PubMed 42029504 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04680403
Lead sponsor
University of Alabama at Birmingham
Responsible party
Stefanie Krick MD (MD, University of Alabama at Birmingham) — Principal investigator
First posted
Dec 23, 2020
Start date
Jul 1, 2022
Primary completion
Jan 1, 2025
Completion
Dec 31, 2025
Last update
Feb 2, 2026

Study contacts

Stefanie Krick
principal investigator · University of Alabama at Birmingham

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion